Internet Archive Scholar

Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of the Okayama Lung Cancer Study Group Trial 0007

Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, Katsuyuki Hotta, Akihiko Tamaoki, Yoshiyuki Tokuda, Takuya Nagata, Kazuhiko Watanabe, Kenichi Gemba, Tomonori Moritaka, Naokatsu Horita, Hiromasa Takeda (+8 others)
2011 Journal of Thoracic Oncology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (274.8 kB)
https://web.archive.org/web/20190303151413/https://core.ac.uk/download/pdf/82227784.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy. Methods: Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the
more » ... 01 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by 2 and t tests, respectively. Results: OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p ϭ 0.109) and 25.6 versus 23.4 (p ϭ 0.064) in the Ն70-year and Ͻ70-year groups, respectively; median PFS (months), 19.0 versus 11.5 (p ϭ 0.175) and 12.0 versus 9.3 (p ϭ 0.132) in the Ն70-year and less than 70-year groups, respectively. Severe toxicity (neutropenia, esophagitis, and pneumonitis) rates did not differ between age groups. Nevertheless, the absence of statistically significant differences in this retrospective analysis might be due to the small number of patients. Radiation intensity was similar between the groups, but chemotherapy intensity was lower in the Ն70-year group. Conclusion: Chemotherapy with concurrent RT may be effective and tolerable in elderly patients with locally advanced non-small cell lung cancer. FIGURE 1. Overall survival of patients in the two randomly assigned treatment arms according to age group (younger than 70 years versus 70 years or older).
doi:10.1097/jto.0b013e318213f86a pmid:21415777 fatcat:t5vuhhktcjf2hal72pj4mkpbzi
Citation

Nagio Takigawa, Katsuyuki Kiura, Yoshihiko Segawa, Katsuyuki Hotta, Akihiko Tamaoki, Yoshiyuki Tokuda, Takuya Nagata, Kazuhiko Watanabe, Kenichi Gemba, Tomonori Moritaka, Naokatsu Horita, Hiromasa Takeda, Niro Okimoto, Mitsuhiro Takemoto, Keitaro Matsuo, Tetsu Shinkai, Masahiro Tabata, Hiroshi Ueoka, Susumu Kanazawa, Mitsune Tanimoto. "Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of the Okayama Lung Cancer Study Group Trial 0007." Journal of Thoracic Oncology 6.6 (2011) 1087-1091